Impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a computational approach.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
25 May 2024
25 May 2024
Historique:
received:
15
08
2023
accepted:
07
05
2024
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
25
5
2024
Statut:
epublish
Résumé
Ebola virus (EBOV) matrix protein VP40 can assemble and bud as virus-like particles (VLPs) when expressed alone in mammalian cells. Nucleoprotein (NP) could be recruited to VLPs as inclusion body (IB) when co-expressed, and increase VLP production. However, the mechanism behind it remains unclear. Here, we use a computational approach to study NP-VP40 interactions. Our simulations indicate that NP may enhance VLP production through stabilizing VP40 filaments and accelerating the VLP budding step. Further, both the relative timing and amount of NP expression compared to VP40 are important for the effective production of IB-containing VLPs. We predict that relative NP/VP40 expression ratio and time are important for efficient production of IB-containing VLPs. We conclude that disrupting the expression timing and amount of NP and VP40 could provide new avenues to treat EBOV infection. This work provides quantitative insights into EBOV proteins interactions and how virion generation and drug efficacy could be influenced.
Identifiants
pubmed: 38796621
doi: 10.1038/s42003-024-06300-8
pii: 10.1038/s42003-024-06300-8
doi:
Substances chimiques
nucleoprotein VP40, Ebola virus
0
Viral Core Proteins
0
Nucleoproteins
0
VP40 protein, virus
0
Viral Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
634Subventions
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : UM1TR004402
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : AI081077
Informations de copyright
© 2024. The Author(s).
Références
Groseth, A., Feldmann, H. & Strong, J. E. The ecology of Ebola virus. Trends Microbiol. 15, 408–416 (2007).
doi: 10.1016/j.tim.2007.08.001
pubmed: 17698361
McElroy, A. K. et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J. Infect. Dis. 210, 558–566 (2014).
doi: 10.1093/infdis/jiu088
pubmed: 24526742
pmcid: 4172044
Ebola Virus Disease Distribution Map: Cases of Ebola Virus Disease in Africa Since 1976 | History | Ebola (Ebola Virus Disease) | CDC. https://www.cdc.gov/vhf/ebola/history/distribution-map.html (2021).
Barbiero, V. K. Ebola: a hyperinflated emergency. Glob. Health Sci. Pract. 8, 178–182 (2020).
doi: 10.9745/GHSP-D-19-00422
pubmed: 32430358
pmcid: 7326525
Aschenbrenner, D. S. Monoclonal antibody approved to treat Ebola. Am. J. Nurs. 121, 22 (2021).
pubmed: 34819468
Markham, A. REGN-EB3: first approval. Drugs 81, 175–178 (2021).
doi: 10.1007/s40265-020-01452-3
pubmed: 33432551
pmcid: 7799152
Adu-Gyamfi, E. et al. The ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J. Biol. Chem. 288, 5779–5789 (2013).
doi: 10.1074/jbc.M112.443960
pubmed: 23297401
pmcid: 3581432
Adu-Gyamfi, E., Digman, M. A., Gratton, E. & Stahelin, R. V. Investigation of Ebola VP40 assembly and oligomerization in live cells using number and brightness analysis. Biophys. J. 102, 2517–2525 (2012).
doi: 10.1016/j.bpj.2012.04.022
pubmed: 22713567
pmcid: 3368128
Hartlieb, B. & Weissenhorn, W. Filovirus assembly and budding. Virology 344, 64–70 (2006).
doi: 10.1016/j.virol.2005.09.018
pubmed: 16364737
Takamatsu, Y., Kolesnikova, L. & Becker, S. Ebola virus proteins NP, VP35, and VP24 are essential and sufficient to mediate nucleocapsid transport. Proc. Natl Acad. Sci. USA 115, 1075–1080 (2018).
doi: 10.1073/pnas.1712263115
pubmed: 29339477
pmcid: 5798334
Beniac, D. R. et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS ONE 7, e29608 (2012).
Johnson, R. F., Bell, P. & Harty, R. N. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol. J. 3, 1–7 (2006).
doi: 10.1186/1743-422X-3-31
Licata, J. M., Johnson, R. F., Han, Z. & Harty, R. N. Contribution of Ebola Virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 Virus-Like Particles. J. Virol. 78, 7344–7351 (2004).
doi: 10.1128/JVI.78.14.7344-7351.2004
pubmed: 15220407
pmcid: 434112
Banadyga, L. et al. Ebola virus VP24 interacts with NP to facilitate nucleocapsid assembly and genome packaging. Sci. Rep. 7, 1–14 (2017).
doi: 10.1038/s41598-017-08167-8
Kirchdoerfer, R. N., Moyer, C. L., Abelson, D. M. & Saphire, E. O. The Ebola virus VP30-NP interaction is a regulator of viral RNA synthesis. PLoS Pathog. 12, 1–22 (2016).
doi: 10.1371/journal.ppat.1005937
Noda, T., Watanabe, S., Sagara, H. & Kawaoka, Y. Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus. J. Virol. 81, 3554–3562 (2007).
doi: 10.1128/JVI.02183-06
pubmed: 17229682
pmcid: 1866061
Wu, L. et al. The two-stage interaction of Ebola virus VP40 with nucleoprotein results in a switch from viral RNA synthesis to virion assembly/budding. Protein Cell 13, 120–140 (2022).
doi: 10.1007/s13238-020-00764-0
pubmed: 33141416
Noda, T., Hagiwara, K., Sagara, H. & Kawaoka, Y. Characterization of the Ebola virus nucleoprotein-RNA complex. J. Gen. Virol. 91, 1478–1483 (2010).
doi: 10.1099/vir.0.019794-0
pubmed: 20164259
pmcid: 2878588
Noda, T. et al. Assembly and budding of Ebolavirus. PLoS Pathog. 2, 0864–0872 (2006).
doi: 10.1371/journal.ppat.0020099
Tao, W., Gan, T., Guo, M., Xu, Y. & Zhong, J. Novel stable Ebola virus minigenome replicon reveals remarkable stability of the viral genome. J. Virol. 91, 1–14 (2017).
doi: 10.1128/JVI.01316-17
Dong, S. et al. Insight into the Ebola virus nucleocapsid assembly mechanism: crystal structure of Ebola virus nucleoprotein core domain at 1.8 Å resolution. Protein Cell 6, 351–362 (2015).
doi: 10.1007/s13238-015-0163-3
pubmed: 25910597
pmcid: 4417675
Schudt, G., Kolesnikova, L., Dolnik, O., Sodeik, B. & Becker, S. Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances. Proc. Natl Acad. Sci. USA 110, 14402–14407 (2013).
doi: 10.1073/pnas.1307681110
pubmed: 23940347
pmcid: 3761630
Yin, J. & Redovich, J. Kinetic modeling of virus growth in cells. Microbiol. Mol. Biol. Rev. 82, 1–33 (2018).
doi: 10.1128/MMBR.00066-17
Liu, X. et al. Mechanisms of phosphatidylserine influence on viral production: a computational model of Ebola virus matrix protein assembly. J. Biol. Chem. 298, 102025 (2022).
doi: 10.1016/j.jbc.2022.102025
pubmed: 35568195
pmcid: 9218153
Liu, X., Husby, M., Stahelin, R. V. & Pienaar, E. Evaluation of fendiline treatment in VP40 system with nucleation-elongation process: a computational model of Ebola virus matrix protein assembly. Microbiol. Spectr. https://doi.org/10.1128/spectrum.03098-23 (2024).
Hoenen, T. et al. Inclusion bodies are a site of ebolavirus replication. J. Virol. 86, 11779–11788 (2012).
doi: 10.1128/JVI.01525-12
pubmed: 22915810
pmcid: 3486333
Mühlberger, E. Filovirus replication and transcription. Future Virol. 2, 205–215 (2007).
doi: 10.2217/17460794.2.2.205
pubmed: 24093048
pmcid: 3787895
Husby, M. L. et al. Phosphatidylserine clustering by the Ebola virus matrix protein is a critical step in viral budding. EMBO Rep. 23, e51709 (2022).
doi: 10.15252/embr.202051709
pubmed: 36094794
pmcid: 9638875
Albariño, C. G., Guerrero, L. W., Chakrabarti, A. K. & Nichol, S. T. Transcriptional analysis of viral mRNAs reveals common transcription patterns in cells infected by five different filoviruses. PLoS One 13, e0201827 (2018).
doi: 10.1371/journal.pone.0201827
pubmed: 30071116
pmcid: 6072132
Bosworth, A. et al. A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus. Sci. Rep. 7, 43144 (2017).
doi: 10.1038/srep43144
pubmed: 28240256
pmcid: 5327407
Mehta, A., Michler, T. & Merkel, O. M. siRNA therapeutics against respiratory viral infections—what have we learned for potential COVID-19 Therapies? Adv. Health. Mater. 10, e2001650 (2021).
doi: 10.1002/adhm.202001650
Dunning, J. et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 13, 1–19 (2016).
doi: 10.1371/journal.pmed.1001997
Kraft, C. S. et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61, 496–502 (2015).
doi: 10.1093/cid/civ334
pubmed: 25904375
pmcid: 4542597
Scott, J. T. et al. Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine 52, 102601 (2020).
Zhang, Y. et al. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. IJMS 23, 2408 (2022).
Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).
Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20 (2020).
Arunachalam, P. S. et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 596, 410–416 (2021).
doi: 10.1038/s41586-021-03791-x
pubmed: 34252919
pmcid: 8761119
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Landeras-Bueno, S. et al. Sudan Ebolavirus VP35-NP crystal structure reveals a potential target for pan-filovirus treatment. mBio 10, 1–13 (2019).
doi: 10.1128/mBio.00734-19
Elliott, L. H., Kiley, M. P. & McCormick, J. B. Descriptive analysis of Ebola virus proteins. Virology 147, 169–176 (1985).
doi: 10.1016/0042-6822(85)90236-3
pubmed: 4060597
Liu, X., Pienaar, E. & Stahelin, R. The impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a mechanistic computational model approach – Code in Matlab. https://doi.org/10.5281/zenodo.8188145 (2023).